Search - tctmd.com

Displaying 261 - 280 of 606

Sort: Relevancy | Date

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

Olive Oil Consumption Linked to CVD Benefits in the US

Shelley Wood

March 09, 2020

News Daily News

One Egg a Day? No Link to Risk of CVD, Mega-Meta-analysis Says

Michael O'Riordan

March 06, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Daily News

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Yael L. Maxwell

January 16, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Shelley Wood

January 14, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Opinion Editor's Corner

ISCHEMIA Questions? Some Answers From David Maron

Shelley Wood

December 09, 2019

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

News Conference News AHA 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Shelley Wood

November 18, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

Advertisement

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Olive Oil Consumption Linked to CVD Benefits in the US

One Egg a Day? No Link to Risk of CVD, Mega-Meta-analysis Says

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

FDA Approves Icosapent Ethyl for Reducing CVD Events

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

ISCHEMIA Questions? Some Answers From David Maron

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content